Muhlenkamp & Co. Inc. purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 114,240 shares of the company’s stock, valued at approximately $7,977,000. Zoetis makes up 1.8% of Muhlenkamp & Co. Inc.’s investment portfolio, making the stock its 22nd largest position.
Other institutional investors have also recently made changes to their positions in the company. Wealthfront Advisers LLC raised its holdings in shares of Zoetis by 80.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after acquiring an additional 33,873 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Zoetis by 16.7% during the 1st quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after acquiring an additional 23,687 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor boosted its position in shares of Zoetis by 21.5% during the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after acquiring an additional 629,974 shares during the last quarter. Nykredit A S purchased a new position in shares of Zoetis during the second quarter worth about $10,042,000. Finally, Flossbach Von Storch SE purchased a new position in shares of Zoetis during the second quarter worth about $302,601,000. Institutional investors own 92.80% of the company’s stock.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Citigroup lowered their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Stifel Nicolaus dropped their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. BTIG Research dropped coverage on shares of Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 price target for the company. Finally, Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. Eight equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $101.25.
Get Our Latest Stock Report on Zoetis
Zoetis Stock Down 1.3%
ZTS opened at $83.32 on Wednesday. The business’s fifty day simple moving average is $76.64 and its 200 day simple moving average is $91.18. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $132.49. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51. The stock has a market cap of $33.85 billion, a PE ratio of 14.17, a P/E/G ratio of 1.22 and a beta of 0.67.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the company posted $1.70 earnings per share. The company’s revenue was down 1.3% compared to the same quarter last year. As a group, research analysts expect that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is currently 36.05%.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
